STUDY DESIGN:
We engineered CF33 to express a CD19t (CF33-CD19t) target. Flow cytometry and ELISA were performed to quantify CD19t expression, immune activation, and killing by virus and CD19-CAR T cells against various pancreatic tumor cells. Subcutaneous pancreatic human xenograft tumor models were treated with virus, CAR T cells, or virus+CAR T cells.
Yes bluebrando, very impressive results from the City of Hope, the above preclinical abstract for publication in the April 2024 Journal of the American College of Surgeons.
There is a very good chance Imugene and the City of Hope to update our early human OASIS results at ASGCT (American Society of Gene and Cell Therapy) to be held on the 7th May or ASCO (American Society of Oncology) on 31 May for our onCARlytics (on-CAR-19, CF33-CD19 HOV4) having cleared the first cohort, for the intratumoural monotherapy lead-in arm result.
Regards.
STUDY DESIGN: We engineered CF33 to express a CD19t (CF33-CD19t)...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.2¢ |
Change
-0.003(3.53%) |
Mkt cap ! $600.2M | |||
| Open | High | Low | Value | Volume |
| 8.5¢ | 8.6¢ | 8.2¢ | $1.246M | 14.84M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 446526 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.3¢ | 535664 | 2 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.2¢ |
Change
-0.003 ( 2.38 %) |
||||
| Open | High | Low | Volume | ||
| 8.6¢ | 8.6¢ | 8.2¢ | 4518456 | ||
| Last updated 15.57pm 03/05/2024 ? | |||||
| IMU (ASX) Chart |